Oncopeptides completes patient enrollment in phase 2 PORT study
- Wednesday, May 5, 2021, 7:04
- Finance
- Add a comment
STOCKHOLM, May 5, 2021 /PRNewswire/ — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the Company has completed patient enrollment in the phase 2 PORT…
About the Author
adminasapcorp has written 41532 stories on this site.